[go: up one dir, main page]

HUP0101269A1 - Káliumcsatorna-inhibítorok - Google Patents

Káliumcsatorna-inhibítorok

Info

Publication number
HUP0101269A1
HUP0101269A1 HU0101269A HUP0101269A HUP0101269A1 HU P0101269 A1 HUP0101269 A1 HU P0101269A1 HU 0101269 A HU0101269 A HU 0101269A HU P0101269 A HUP0101269 A HU P0101269A HU P0101269 A1 HUP0101269 A1 HU P0101269A1
Authority
HU
Hungary
Prior art keywords
alkylene
alkyl
heterocyclyl
nhc
heteroaryl
Prior art date
Application number
HU0101269A
Other languages
English (en)
Inventor
Neil A. Castle
Michael F. Gross
Original Assignee
Icagen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icagen, Inc. filed Critical Icagen, Inc.
Publication of HUP0101269A1 publication Critical patent/HUP0101269A1/hu
Publication of HUP0101269A3 publication Critical patent/HUP0101269A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Magnetic Heads (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Seasonings (AREA)
  • Sorption Type Refrigeration Machines (AREA)
  • External Artificial Organs (AREA)

Abstract

Az (I) általános képletű vegyületek - a képletben t értéke 1 vagy 2; Aés B jelentése külön-külön H, vagy együtt kötést képeznek aszubsztituált szénatomok között; R1 jelentése H, alkil-, vagy adottesetben szubsztituált aril-, heteroaril-, heterociklil- vagykarbocikloalkilcsoport; Y2 jelentése (CH2)q, (CH2)WO, HC=CH vagyetinilcsoport; X2 jelentése C=O, C=S vagy SO2; R3 és R4 jelentéseegymástól függetlenül H, alkil- vagy adott esetben szubsztituáltaril-, aralkil-, heteroaril-, hetero-aralkil-, heterociklil-,karbocikloalkilcsoport vagy alki-lén-(szubsztituált amino)-csoport; Zjelentése H, alkil-, alkienil-, alkilén(heterociklil)-, alkilén--(heteroaril)-, alkilén-NHC(O)(alkil)--, alkilén-NH-C(O)(aril)-,alkilén-NHC(O)(heterociklil)-, alkilén-NHC(O)(heteroaril)-, alkilén-NHC(O)(alkilén-heterociklil)-, alkilén-NHC(O)-(heteroaralkil)-,alkilén-C(O)-(alkil)-, alkilén-C(O)O(alkil)-, OR14, SR14 vagy NR15R16csoport; R2 jelentése H, alkil-, adott esetben szubsztituált aril-,aralkil-, heteroaril-, heterociklil-, heteroaralkil-,karbocikloalkilcsoport, Ra-O- vagy RbRc-N- csoport; Y1 jelentése(CH2)p, CHR17(CH2)o, HC=CH vagy etinilcsoport; X1 jelentése C=O, C=S,SO2 vagy (CH2)n - és gyógyászatilag elfogadható sóik vagy prodrogjaikkáliumcsatorna inhibitor aktivitásuk következtében szívaritmiák éssejtproliferatív rendellenességek kezelésére alkalmazhatók. Ó
HU0101269A 1998-01-27 1999-01-27 Potassium channel inhibitors HUP0101269A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7271998P 1998-01-27 1998-01-27
PCT/US1999/001663 WO1999037607A1 (en) 1998-01-27 1999-01-27 Potassium channel inhibitors

Publications (2)

Publication Number Publication Date
HUP0101269A1 true HUP0101269A1 (hu) 2001-10-28
HUP0101269A3 HUP0101269A3 (en) 2003-01-28

Family

ID=22109343

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101269A HUP0101269A3 (en) 1998-01-27 1999-01-27 Potassium channel inhibitors

Country Status (21)

Country Link
US (1) US6333337B1 (hu)
EP (1) EP1051394B1 (hu)
JP (1) JP2002501041A (hu)
KR (1) KR20010034377A (hu)
CN (1) CN1294577A (hu)
AT (1) ATE265426T1 (hu)
AU (1) AU745845B2 (hu)
BR (1) BR9907236A (hu)
CA (1) CA2317457A1 (hu)
DE (1) DE69916792D1 (hu)
HU (1) HUP0101269A3 (hu)
ID (1) ID25853A (hu)
IL (1) IL137219A0 (hu)
NO (1) NO20003600L (hu)
NZ (1) NZ505666A (hu)
PL (1) PL341859A1 (hu)
RU (1) RU2218330C2 (hu)
TR (1) TR200002191T2 (hu)
TW (1) TW542823B (hu)
WO (1) WO1999037607A1 (hu)
ZA (1) ZA99550B (hu)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333349B1 (en) * 1997-02-26 2001-12-25 Aventis Pharma Deutschland Gmbh Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them
CA2341678C (en) 1998-09-01 2009-10-13 Bristol-Myers Squibb Company Potassium channel inhibitors and method
WO2001021648A1 (en) * 1999-09-22 2001-03-29 Cognetix, Inc. Uses of kappa-conotoxin pviia
JP2003518101A (ja) * 1999-12-21 2003-06-03 アイカゲン インコーポレイテッド カリウムチャネル阻害剤
US6566380B2 (en) * 2000-07-25 2003-05-20 Icagen, Inc. Potassium channel inhibitors
US6620849B2 (en) 2000-07-26 2003-09-16 Icafen, Inc. Potassium channel inhibitors
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) * 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6849634B2 (en) 2000-12-21 2005-02-01 Icagen Potassium channel inhibitors
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US7470518B2 (en) 2002-02-12 2008-12-30 Cellectricon Ab Systems and method for rapidly changing the solution environment around sensors
EP2368636A3 (en) 2002-02-12 2012-03-07 Cellectricon Ab Systems and methods for rapidly changing the solution environment around sensors
US20030199578A1 (en) * 2002-04-19 2003-10-23 Turner Sean C. Naphthalene amides as potassium channel openers
BR0309940A (pt) * 2002-05-08 2005-02-09 Bayer Healthcare Ag Derivados de hidróxi-tetraidro-naftaleniluréia
WO2004052846A1 (en) * 2002-12-06 2004-06-24 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives
ATE404531T1 (de) * 2002-12-09 2008-08-15 Xention Ltd Tetrahydronaphtalen-derivate als vanilloid- rezeptor-antagonisten
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
EA010186B1 (ru) 2003-10-08 2008-06-30 Шеринг Акциенгезельшафт Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
US7638515B2 (en) 2003-10-08 2009-12-29 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7662821B2 (en) 2003-10-08 2010-02-16 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US20080153859A1 (en) 2004-04-05 2008-06-26 Hartmut Rehwinkel Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
DE102005017316A1 (de) * 2005-04-14 2006-10-19 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
EP1834948A1 (de) 2006-03-15 2007-09-19 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
RU2008144805A (ru) * 2006-04-14 2010-05-20 Новартис АГ (CH) Применение биарилкарбоксамидов в лечении заболеваний, связанных с hedgehog-путем
DE102006019589A1 (de) * 2006-04-27 2007-10-31 Sanofi-Aventis Deutschland Gmbh Inhibitoren des TASK-1 und Task-3 Ionenkanals
JP5419691B2 (ja) * 2006-08-23 2014-02-19 バレアント ファーマシューティカルズ インターナショナル カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体
AU2007325629A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (hu) 2011-07-01 2018-04-28
CA2862670A1 (en) 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
CA3151863C (en) 2021-10-27 2024-01-02 Shanghai Zhimeng Biopharma, Inc. Compound as potassium channel regulator and preparation and use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953506A (en) 1974-02-07 1976-04-27 American Cyanamid Company Ureidotetralin compounds
US4005140A (en) 1974-02-07 1977-01-25 American Cyanamid Company Ureidotetralin compounds
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
GB8707123D0 (en) 1987-03-25 1987-04-29 Pfizer Ltd Antiarrhythmic agents
US5006512A (en) 1987-10-02 1991-04-09 Tsuyoshi Ohnishi Therapeutic usages of inhibitors for a potassium efflux channel
IL88314A (en) 1987-11-18 1994-05-30 Tanabe Seiyaku Co Sulphonylamino indane derivatives, their preparation and pharmaceutical compositions containing them
AU609232B2 (en) 1987-12-14 1991-04-26 Beecham Group Plc Novel indane derivatives possessing smooth muscle relaxant activity
US5242947A (en) 1988-02-10 1993-09-07 New York University Use of polyamines as ionic-channel regulating agents
DE3818245A1 (de) 1988-05-28 1989-12-07 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln
ES2123500T3 (es) * 1989-05-31 1999-01-16 Upjohn Co Derivados de 8-heterociclil-2-aminotetralina activos sobre el sistema nervioso central.
US5215985A (en) 1990-07-20 1993-06-01 E. R. Squibb & Sons, Inc. Method for treating ischemic insult to neurons employing an ATP-sensitive potassium channel blocker
EP0472053B1 (en) 1990-08-20 1998-06-17 Eisai Co., Ltd. Sulfonamide derivatives
US5401848A (en) 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
US5310932A (en) 1991-04-15 1994-05-10 E. R. Squibb & Sons, Inc. Chromanyl substituted indole potassium channel openers
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5356775A (en) 1992-07-29 1994-10-18 Brigham & Women's Hospital Primary structure for functional expression from complementary DNA of a mammalian ATP-sensitive potassium channel
US5328830A (en) 1992-09-08 1994-07-12 Miles Inc. Potassium channel modulators
US5374643A (en) 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
US5453421A (en) 1992-09-11 1995-09-26 E. R. Squibb & Sons, Inc. Aryl and heterocyclic substituted propenamide derivatives
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9309716D0 (en) 1993-05-12 1993-06-23 Zeneca Ltd Heterocyclic derivatives
US5401758A (en) 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds
US5631275A (en) 1993-12-30 1997-05-20 Hoechst Aktiengesellschaft Substituted benzenesulfonylureas and -thioureas, preparation processes and possible uses of pharmaceutical preparations based on these compounds
FR2717805B1 (fr) 1994-03-28 1996-05-10 Rhone Poulenc Rorer Sa Dérivés de 5H-indeno[1,2-b]pyrazine-2,3-dione, leur préparation et les médicaments les contenant .
US5615460A (en) 1994-06-06 1997-04-01 The Procter & Gamble Company Female component for refastenable fastening device having regions of differential extensibility
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
WO1996036596A1 (en) 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU1582197A (en) 1996-01-22 1997-08-11 Eli Lilly And Company Combinatorial process for preparing substituted indane libraries
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US6048877A (en) 1997-02-21 2000-04-11 Bristol-Myers Squibb Company Tetralone derivatives as antiarrhythmic agents

Also Published As

Publication number Publication date
AU745845B2 (en) 2002-04-11
HUP0101269A3 (en) 2003-01-28
KR20010034377A (ko) 2001-04-25
EP1051394B1 (en) 2004-04-28
CN1294577A (zh) 2001-05-09
US6333337B1 (en) 2001-12-25
PL341859A1 (en) 2001-05-07
NO20003600L (no) 2000-09-26
NO20003600D0 (no) 2000-07-13
ID25853A (id) 2000-11-09
AU2241999A (en) 1999-08-09
TR200002191T2 (tr) 2000-11-21
NZ505666A (en) 2002-11-26
TW542823B (en) 2003-07-21
DE69916792D1 (de) 2004-06-03
BR9907236A (pt) 2002-01-22
JP2002501041A (ja) 2002-01-15
RU2218330C2 (ru) 2003-12-10
ATE265426T1 (de) 2004-05-15
ZA99550B (en) 1999-07-26
IL137219A0 (en) 2001-07-24
WO1999037607A1 (en) 1999-07-29
EP1051394A1 (en) 2000-11-15
CA2317457A1 (en) 1999-07-29

Similar Documents

Publication Publication Date Title
HUP0101269A1 (hu) Káliumcsatorna-inhibítorok
NO20014485L (no) Nye forbindelser og sammensetninger som proteaseinhibitorer
AR042438A1 (es) Derivados de fluorglicosidos aromaticos, medicamentos que contienen estos compuestos y sus usos
CA2263983A1 (en) Cyclic amine derivatives for inhibiting blood platelet aggregation
MY142846A (en) Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
LU90026I2 (fr) Topotecan et ses sels et dérivés pharmaceutiquement acceptables (Hycamtin R)
CA2139109A1 (en) Purinone Antianginal Agents
EP1389110A4 (en) INHIBITORS OF MACROPHAGE MIGRATION INHIBITOR FACTOR AND METHODS OF IDENTIFYING SUCH INHIBITORS
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
AR049670A1 (es) Un derivado de acido aminometil carboxilico, su uso en el tratamiento de alteraciones del snc y una composicion farmaceutica que lo contiene
ATE399171T1 (de) Camptothecinanaloge und deren zubereitungsmethoden
CO5611143A2 (es) Profarmacos de fosfatos de fluorooxindoles
NO20033710D0 (no) Fenylalaninenamid-derivater som har en cyklobutengruppe, for anvendelse somintegrin-inhibitorer
TR200000993T2 (tr) Endotelin antagonistleri.
WO2003101996A3 (en) Esters in position 20 of camptothecins
MY135646A (en) Indolyl derivatives
DK0861250T3 (da) Amindin- og isothiourinstofderivater som inhibitorer for nitrogenmonoxidsyntase
ATE229800T1 (de) Guanidino proteiase inhibitoren
EA200300272A1 (ru) Новые производные хиназолина, способ их получения и фармацевтические композиции, содержащие их
BR0311333A (pt) ésteres na posição 20 de camptotecinas
MD1744F2 (ro) Săruri ale acidului clavulanic şi procedeu de obţinere a lor
EA199700147A1 (ru) Замещенные фенильные производные в качестве антагонистов эндотелина
DK0669316T3 (da) Analoge til 15-deoxyspergualin, metode til deres fremstilling og deres anvendelse som immunoundertrykkende midler
ATE286395T1 (de) Antithrombotische mittel
EA200701248A1 (ru) Новые спиротропановые соединения и способы модуляции активности рецептора хемокина

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees